Immunic, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
Immunic, Inc. (IMUX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 3.80% for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-20.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2015-03-20
- Immunic, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2014 was 3.80%, a 2.56% decline from fiscal 2013.
- Immunic, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2013 was 3.90%, a 116.67% increase from fiscal 2012.
- Immunic, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2012 was 1.80%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2014-12-31 | 3.80% 10-K · filed 2015-03-20 |
| 2013-12-31 | 3.90% 10-K · filed 2015-03-20 |
| 2012-12-31 | 1.80% 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B |